• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性血管内皮生长因子受体-1和内皮抑素在肺癌患者恶性胸腔积液中的诊断价值

Diagnostic Values of sVEGFR-1 and Endostatin in Malignant Pleural Effusions in Patients with Lung Cancer.

作者信息

Zhu Ying-Ying, Wu Hui-Mei, Liu Rong-Yu

出版信息

Clin Lab. 2017 Sep 1;63(9):1371-1378. doi: 10.7754/Clin.Lab.2017.170217.

DOI:10.7754/Clin.Lab.2017.170217
PMID:28879702
Abstract

BACKGROUND

The diagnosis of malignant pleural effusion (MPE) remains a common clinical challenge because of the sensitivity of conventional cytology for the detection is insufficient. Thus, a sensitive clinical marker for diagnosis is required. The aim of this study was to assess the role of two anti-angiogenic cytokines, soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and endostatin, in diagnosing MPE.

METHODS

Effusion samples from 44 patients with MPE caused by lung cancer and from 36 patients with benign pleural effusion (BPE) were collected. The concentrations of sVEGFR-1 and endostatin in pleural fluid were determined by an enzyme-linked immunosorbent assay (ELISA). The diagnostic performance was measured by receiver operating characteristic curves (ROCs).

RESULTS

The levels of sVEGFR-1 and endostatin in MPE due to lung cancer were significantly higher than those in BPE (p < 0.05). The sensitivity and specificity of endostatin were 52.27% and 86.11%, respectively, while for sVEGFR-1, the sensitivity was 88.64% and the specificity was 58.33%. Interestingly, the combination of sVEGFR1 and endostatin produced better sensitivity and specificity of 72.73% and 83.33%, respectively. In addition, the levels of sVEGFR-1 and endostatin were significantly related to each other (p < 0.05), and the levels of endostatin in bloody effusions were significantly higher than those in non-bloody effusions (p < 0.05).

CONCLUSIONS

Our study indicated that the levels of sVEGFR-1 and endostatin were significantly elevated in MPE. The combined detection of sVEGFR-1 and endostatin may be useful in the diagnosis of MPE.

摘要

背景

由于传统细胞学检测恶性胸腔积液(MPE)的敏感性不足,其诊断仍是一项常见的临床挑战。因此,需要一种敏感的诊断临床标志物。本研究的目的是评估两种抗血管生成细胞因子,可溶性血管内皮生长因子受体-1(sVEGFR-1)和内皮抑素在MPE诊断中的作用。

方法

收集44例肺癌所致MPE患者和36例良性胸腔积液(BPE)患者的胸水样本。采用酶联免疫吸附测定(ELISA)法测定胸水中sVEGFR-1和内皮抑素的浓度。通过受试者工作特征曲线(ROC)评估诊断性能。

结果

肺癌所致MPE中sVEGFR-1和内皮抑素水平显著高于BPE(p<0.05)。内皮抑素的敏感性和特异性分别为52.27%和86.11%,而sVEGFR-1的敏感性为88.64%,特异性为58.33%。有趣的是,sVEGFR1和内皮抑素联合检测的敏感性和特异性更好,分别为72.73%和83.33%。此外,sVEGFR-1和内皮抑素水平显著相关(p<0.05),血性胸水中内皮抑素水平显著高于非血性胸水(p<0.05)。

结论

我们的研究表明,MPE中sVEGFR-1和内皮抑素水平显著升高。sVEGFR-1和内皮抑素联合检测可能有助于MPE的诊断。

相似文献

1
Diagnostic Values of sVEGFR-1 and Endostatin in Malignant Pleural Effusions in Patients with Lung Cancer.可溶性血管内皮生长因子受体-1和内皮抑素在肺癌患者恶性胸腔积液中的诊断价值
Clin Lab. 2017 Sep 1;63(9):1371-1378. doi: 10.7754/Clin.Lab.2017.170217.
2
Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions.血管内皮生长因子和内皮抑素在恶性胸腔积液中的诊断价值
Int J Tuberc Lung Dis. 2009 Mar;13(3):381-6.
3
Diagnostic accuracy of endostatin for malignant pleural effusion: A clinical study and meta-analysis.内皮抑素对恶性胸腔积液的诊断准确性:一项临床研究与荟萃分析。
Postgrad Med. 2015 Jun;127(5):529-34. doi: 10.1080/00325481.2015.1048180. Epub 2015 May 15.
4
Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.VEGF和内皮抑素对肺癌患者恶性胸腔积液的预后价值。
Asian Pac J Cancer Prev. 2014;15(19):8435-40. doi: 10.7314/apjcp.2014.15.19.8435.
5
Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions.渗出性胸腔积液中可溶性血管内皮生长因子受体1水平升高。
J Med Invest. 2007 Feb;54(1-2):146-53. doi: 10.2152/jmi.54.146.
6
[The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].[B7-H4与癌胚抗原在诊断良恶性胸腔积液中的价值]
Zhonghua Zhong Liu Za Zhi. 2017 Jul 23;39(7):524-527. doi: 10.3760/cma.j.issn.0253-3766.2017.07.009.
7
Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.SiSo细胞表达的可溶性受体结合癌抗原和癌胚抗原在鉴别恶性与良性胸腔积液中的诊断价值
Tumour Biol. 2016 Mar;37(3):3257-64. doi: 10.1007/s13277-015-4174-8. Epub 2015 Oct 5.
8
Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer.血管内皮生长因子mRNA和内皮抑素mRNA在肺癌患者胸腔积液中的转录表达及临床意义
Diagn Cytopathol. 2012 Apr;40(4):287-91. doi: 10.1002/dc.21546. Epub 2010 Oct 26.
9
Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.内皮细胞特异性分子-1对非小细胞肺癌患者恶性胸腔积液的诊断及预后价值
Oncotarget. 2017 Jul 25;8(30):49217-49223. doi: 10.18632/oncotarget.17455.
10
Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion.评估肺癌合并胸腔积液患者血清和胸腔液中内皮抑素和血管内皮生长因子的水平。
Asian Pac J Trop Med. 2012 Mar;5(3):239-42. doi: 10.1016/S1995-7645(12)60032-7.

引用本文的文献

1
Development and validation of a machine learning model for differential diagnosis of malignant pleural effusion using routine laboratory data.基于常规实验室数据的机器学习模型对恶性胸腔积液进行鉴别诊断的建立与验证。
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208632. doi: 10.1177/17534666231208632.
2
The Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion.贝伐单抗联合铂类胸腔灌注治疗恶性胸腔积液的Meta分析
J Oncol. 2022 Feb 25;2022:1476038. doi: 10.1155/2022/1476038. eCollection 2022.
3
Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.
恶性胸腔积液诊断中的胸膜生物标志物:一项叙述性综述
Transl Lung Cancer Res. 2021 Mar;10(3):1557-1570. doi: 10.21037/tlcr-20-1111.
4
Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression.肿瘤微环境:细胞外基质改变影响肿瘤进展。
Front Oncol. 2020 Apr 15;10:397. doi: 10.3389/fonc.2020.00397. eCollection 2020.